Phoenix (March 4, 2016) - 113 early stage companies applied to compete in the third annual Venture Madness competition - a bracket-style business competition modeled after the NCAA March Madness basketball tournament. The applicant pool was narrowed down to 64 companies which began competing head-to-head online to try to enter the Sweet 16. The top 16 finalists including NuvOx competed in an in-person live pitch event at the Talking Stick Resort in Scottsdale over a three day period.
Tucson (Feb. 14, 2016) - Tucson based pharmaceutical company NuvOx Pharma announced today that it has secured orphan drug designation from the FDA for its investigational drug NVX-508 for vaso-occlusive crisis (VOC) and acute chest syndrome (ACS) in sickle cell disease...
Tucson (Feb. 13, 2016) - The FDA has notified NuvOx Pharma that it may proceed with a clinical trial for its Investigational New Drug (IND), NVX-508 for vaso-occlusive crisis (VOC) and acute chest syndrome (ACS) in sickle cell disease. VOC is one of the most severe complications of sickle cell disease and it typically involves excruciating, debilitating, episodic pain and can contribute to contribute to infection, stroke, multisystem organ damage, and shortened life expectancy.
TUCSON (Dec. 4, 2015) - Tucson based pharmaceutical company NuvOx Pharma announced today that it has secured orphan drug designation from the FDA for its investigational radiosensitizer for glioblastoma multiforme. Glioblastoma is the most prevalent and aggressive form of brain cancer. Over 10,000 new patients are diagnosed with glioblastoma in the U.S. each year. Despite advances in surgery, radiation, and chemotherapy, recurrence is almost a certainty, occurring on average in less than a year. Survival is poor and fewer than 10% of these patients live more than five years.
TUCSON (Nov. 30, 2015) - Evan Unger, MD, President and CEO of NuvOx, said, “We are pleased to announce that our platform technology oxygen therapeutic has shown pharmacodynamic effects in our Phase 1b clinical trial in Glioblastoma multiforme (GBM). We are observing radiation sensitizing pharmacodynamics effects that have presumed therapeutic efficacy. We are confirming this with the addition of 3 additional patients at the dose of 0.1 cc/kg of NVX-108. Read More
To read more news about NuvOx Pharma, please visit our news page.
To view more NuvOx Pharma publications, please visit our publication page.
This is a comprehensive presentation of the company's Oxygen Nanotechnology Platform for treating life threatening conditions.
Dr. Unger has pioneered original research, championed the clinical translation of his research products, and founded companies in the technology-based private sector to market these products. Dr. Unger's products are routinely used in clinical diagnostic tests that impact the lives of Arizonans and improve healthcare world-wide.
NuvOx Pharma's CBO, David Wilson presents life saving innovation at AZBio Expo 2013
11th in a series of interviews from the ICUS Bubble Conference
Updated Cochrane review comparing types of toothbrushes finds some difference in the short-term. [...]
Reviewers from Finland's national medicines agency study medicated skin treatments and shampoo [...]
The latest from the updated Cochrane Collaboration systematic review on exercise for people with hea [...]
A review from the US Agency for Healthcare Quality and Research (AHRQ) analyzes evidence about speci [...]
An individual patient data meta-analysis analyzes CBT website impact on moderate versus mild depress [...]